Your browser is no longer supported. Please, upgrade your browser.
ARTL Artelo Biosciences, Inc. daily Stock Chart
Artelo Biosciences, Inc.
Index- P/E- EPS (ttm)-1.24 Insider Own19.20% Shs Outstand3.43M Perf Week-4.20%
Market Cap4.92M Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float2.50M Perf Month7.87%
Income-3.90M PEG- EPS next Q-0.40 Inst Own0.40% Short Float0.15% Perf Quarter18.11%
Sales- P/S- EPS this Y-336.10% Inst Trans7.49% Short Ratio0.02 Perf Half Y-41.95%
Book/sh1.08 P/B1.27 EPS next Y-0.60% ROA-89.20% Target Price- Perf Year30.48%
Cash/sh0.56 P/C2.46 EPS next 5Y- ROE-108.40% 52W Range0.61 - 5.00 Perf YTD-49.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.60% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low124.59% ATR0.21
Employees3 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)54.95 Volatility25.58% 16.43%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume3.20 Prev Close1.63
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume180.79K Price1.37
Recom2.00 SMA206.61% SMA5017.98% SMA200-25.41% Volume578,941 Change-15.95%
Jun-03-20 09:30AM  
May-12-20 09:30AM  
May-06-20 09:09AM  
Apr-14-20 08:30AM  
Mar-23-20 09:00AM  
Mar-02-20 09:07AM  
Feb-24-20 09:00AM  
Feb-03-20 11:42AM  
Jan-29-20 09:00AM  
Jan-14-20 08:00AM  
Dec-09-19 08:30AM  
Nov-25-19 08:00AM  
Nov-18-19 08:30AM  
Nov-14-19 09:00AM  
Oct-29-19 08:30AM  
Oct-22-19 09:00AM  
Sep-18-19 08:00AM  
Sep-11-19 09:00AM  
Sep-04-19 01:34PM  
Jul-15-19 04:01PM  
Jul-10-19 07:23AM  
Jun-25-19 01:00PM  
May-08-19 04:05PM  
Jan-03-19 07:00AM  
Oct-09-18 08:00AM  
Jul-03-18 08:00AM  
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system and related signaling pathways. Its product pipeline includes ART27.13, a cannabinoid agonist for the treatment of anorexia associated with cancer; ART12.11, a CBD cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is headquartered in La Jolla, California.